Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled date : 2021 - 10 - 04 save search
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
Published: 2021-10-04 (Crawled : 20:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.23%
H: 0.57%
C: -1.6%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 1.32%
C: 0.31%
treatment
Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder
Published: 2021-10-04 (Crawled : 15:00) - biospace.com/
RLMD | $4.0 -6.98% -7.5% 150K
|
Health Technology
|
| O: -0.34%
H: 2.89%
C: 0.64%
treatment ongoing depression major depressive disorder
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
ARQT A | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.56%
H: 0.24%
C: -1.54%
new drug psoriasis treatment fda drug application plague
New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2021-10-04 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.5%
H: 2.54%
C: 1.45%
multiple sclerosis treatment sclerosis
C-RAD and Accuray Sign Agreement to Enhance Radixact® System Breast Cancer Treatment Capabilities
Published: 2021-10-04 (Crawled : 13:15) - biospace.com/
ARAY | $2.135 -3.39% -3.51% 630K
|
Health Technology
|
| O: 0.49%
H: 0.49%
C: -1.23%
treatment cancer breast cancer
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted grant designation
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Published: 2021-10-04 (Crawled : 13:15) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
TPTX | $76.01 -0.03%
|
Health Technology
|
| O: -0.53%
H: 2.39%
C: -0.01%
treatment solid tumors positive therapy breakthrough therapy granted designation
Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease
Published: 2021-10-04 (Crawled : 12:15) - prnewswire.com
IKT | News | $2.1 0.19% 52K
|
Health Technology
|
| O: 2.32%
H: 2.77%
C: -1.77%
disease treatment results parkinson ikt-148009
FDA Grants Orphan Drug Designation (ODD) to AlloVir’s Posoleucel, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell Therapy, for the Treatment of Virus-Associated Hemorrhagic Cystitis
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ALVR | $0.7505 1.13% 1.12% 340K
|
Health Technology
|
| O: 6.01%
H: 0.0%
C: -13.5%
treatment fda orphan drug therapy drug t-cell tollovir designation
Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - globenewswire.com
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.98%
H: 0.63%
C: -0.48%
XNCR | $18.385 -2.98% -3.07% 830K
|
Health Technology
|
| O: 2.87%
H: 5.64%
C: 5.37%
treatment collaboration antibody license t-cell
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Published: 2021-10-04 (Crawled : 12:00) - biospace.com/
ZLAB | News | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -4.58%
H: 2.65%
C: 0.49%
NVCR | $12.09 0.33% 0.33% 850K
|
Health Technology
|
| O: -1.34%
H: 0.07%
C: -5.6%
treatment phase 2 china therapy cancer trial enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.